Highlights: Dear Fellow Shareholders, On behalf of the Company I’m pleased to present our final Quarterly Update for FY 2024. As we approach a pivotal moment in our journey, I’m thrilled to highlight our recent achievements and the exciting developments on the horizon. Our dedicated efforts across various sectors have led to impressive financial results...
Tag: investing news
Post
Post
Far Northern Resources Quarterly June Report 2024
During the June quarter 2024 Far Northern Resources Ltd (ASX:FNR) successfully raised $4.16 million and was accepted to admission to the official list of the Australian Stock Exchange (ASX). Shares in FNR started trading on the 12th of April 2024. The Initial Public Offering (IPO) raised $4,165,000 through the issue of 20,825,000 shares at an...
Post
Post
Post
Quarterly Activities and Cashflow Report June 2024
Description Highlights source
Post
Quarterly Activities Report for the Quarter Ended 30 June 2024
ORROROO URANIUM PROJECT • Exploration planning and stakeholder engagement continues at Orroroo • Subsequent to period end a Site visit, Drilling Campaign Radiation Safety Report and all required Rehabilitation Works have been completed at Orroroo ROGER RIVER PROJECT • Evaluating tenure and packing/shipment of maiden drilling diamond drill core to Mineral Resources Tasmania storage facility...
Post
Redstone Resources Quarterly Report for the Period Ending 30 June 2024
WEST MUSGRAVE COPPER PROJECT (100% RDS) – WEST MUSGRAVE, WESTERN AUSTRALIA source
Post
Disrupting China’s Hard-rock Lithium Conversion Dominance
You can’t make lithium-ion batteries, a critical component of electric vehicles (EVs) and other devices of the new green economy, without lithium. But securing a stable, secure and politically neutral supply chain for so-called white gold is a challenge. Hard-rock lithium conversion entails converting mined lithium spodumene ore into lithium sulfate, then battery-grade lithium carbonate...
Post
CLEO Selects U.S. Clinical Trial Sites
U.S. Clinical Trial Sites Selected CLEO is pursuing regulatory approval in the U.S. as the largest diagnostics market in the world. Prior to submission with the Food and Drug Administration (FDA), the Company will complete a study that will benchmark CLEO’s technology through a 500 patient clinical trial. CLEO’s U.S.-based clinical trials manager, Lindus Health,...
Post
Gold's Record Q2 Fueled by Rise in OTC Investment and Strong Central Bank Buying
Continued central bank buying was also a key reason why the yellow metal achieved record highs in Q2. Gold demand excluding OTC decreased by 6 percent year-on-year in Q2 to reach 929 metric tons (MT). This decline was primarily driven by a drop in jewelry consumption, which fell by 19 percent year-on-year to a four...